Biosynex Asset Resilience Ratio

Latest as of June 2025: 3.35%

Biosynex asset resilience ratio. Biosynex (ALBIO) has an Asset Resilience Ratio of 3.35% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ALBIO defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€5.00 Million
≈ $5.85 Million USD Cash + Short-term Investments

Total Assets

€149.44 Million
≈ $174.71 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Biosynex (2011–2024)

Asset resilience ratio of Biosynex from 2011 to 2024. This chart shows how Biosynex's Asset Resilience Ratio has changed over time. Read Biosynex debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Biosynex's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Biosynex's balance sheet.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €5.00 Million 3.35%
Total Liquid Assets €5.00 Million 3.35%

Asset Resilience Insights

  • Limited Liquidity: Biosynex maintains only 3.35% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Biosynex Industry Peers by Asset Resilience Ratio

Compare Biosynex's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
HOB Biotech Group Corp Ltd
SHG:688656
Medical Devices 2.62%
L&C Bio Co. Ltd
KQ:290650
Medical Devices 2.14%
Applied BioCode
TW:6598
Medical Devices 9.75%
Oncosil Medical Ltd
AU:OSL
Medical Devices 0.00%
Cleo Diagnostics Ltd
AU:COV
Medical Devices 94.64%
Radiant Innovation
TWO:3373
Medical Devices 0.82%
Impedimed Ltd
AU:IPD
Medical Devices 46.15%
Memphasys Ltd
AU:MEM
Medical Devices 0.00%

Biosynex Asset Resilience Ratio by Year (2011–2024)

Biosynex asset resilience ratio by year from 2011 to 2024. The table below shows the annual Asset Resilience Ratio data for Biosynex.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 2.57% €5.00 Million
≈ $5.85 Million
€194.69 Million
≈ $227.61 Million
+0.09pp
2023-12-31 2.48% €6.00 Million
≈ $7.01 Million
€241.73 Million
≈ $282.61 Million
+2.48pp
2022-12-31 0.00% €1.00
≈ $1.17
€259.98 Million
≈ $303.94 Million
-0.90pp
2021-12-31 0.90% €2.42 Million
≈ $2.83 Million
€268.94 Million
≈ $314.42 Million
-3.21pp
2020-12-31 4.11% €5.18 Million
≈ $6.06 Million
€126.07 Million
≈ $147.39 Million
+1.54pp
2019-12-31 2.57% €1.22 Million
≈ $1.42 Million
€47.34 Million
≈ $55.35 Million
+1.92pp
2018-12-31 0.65% €257.50K
≈ $301.04K
€39.46 Million
≈ $46.14 Million
-4.33pp
2017-12-31 4.98% €2.02 Million
≈ $2.36 Million
€40.51 Million
≈ $47.36 Million
+3.46pp
2016-12-31 1.52% €599.22K
≈ $700.55K
€39.51 Million
≈ $46.19 Million
-23.11pp
2013-12-31 24.63% €1.80 Million
≈ $2.10 Million
€7.31 Million
≈ $8.55 Million
-10.98pp
2012-12-31 35.61% €3.15 Million
≈ $3.68 Million
€8.85 Million
≈ $10.34 Million
-35.56pp
2011-12-31 71.16% €4.33 Million
≈ $5.06 Million
€6.09 Million
≈ $7.12 Million
--
pp = percentage points

About Biosynex

PA:ALBIO France Medical Devices
Market Cap
$17.67 Million
€15.11 Million EUR
Market Cap Rank
#25683 Global
#418 in France
Share Price
€0.82
Change (1 day)
-3.07%
52-Week Range
€0.48 - €1.57
All Time High
€25.28
About

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hyg… Read more